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Abstract
Background: Weekly docetaxel has occasionally been used in the neoadjuvant to downstage breast cancer to
reduce toxicity and possibly enhance quality of life. However, no studies have compared the standard three weekly
regimen to the weekly regimen in terms of quality of life. The primary aim of our study was to compare the
effects on QoL of weekly versus 3-weekly sequential neoadjuvant docetaxel. Secondary aims were to determine the
clinical and pathological responses, incidence of Breast Conserving Surgery (BCS), Disease Free Survival (DFS) and
Overall Survival (OS).
Methods: Eighty-nine patients receiving four cycles of doxorubicin and cyclophosphamide were randomised to
receive twelve cycles of weekly docetaxel (33 mg/m
2) or four cycles of 3-weekly docetaxel (100 mg/m
2). The
Functional Assessment of Cancer Therapy-Breast and psychosocial questionnaires were completed.
Results: At a median follow-up of 71.5 months, there was no difference in the Trial Outcome Index scores
between treatment groups. During weekly docetaxel, patients experienced less constipation, nail problems,
neuropathy, tiredness, distress, depressed mood, and unhappiness. There were no differences in overall clinical
response (93% vs. 90%), pathological complete response (20% vs. 27%), and breast-conserving surgery (BCS) rates
(49% vs. 42%). Disease-free survival and overall survival were similar between treatment groups.
Conclusions: Weekly docetaxel is well-tolerated and has less distressing side-effects, without compromising
therapeutic responses, Breast Conserving Surgery (BCS) or survival outcomes in the neoadjuvant setting.
Trial registration: ISRCTN: ISRCTN09184069
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Neoadjuvant chemotherapy (NAC) is being used with
increasing frequency in the treatment of patients with
locally advanced breast cancers (LABCs) [1]. It has been
considered for operable breast cancer in order to down-
stage the disease and enable breast-conserving surgery
(BCS) to be carried out [2,3]. NAC may deal with occult
micrometastases, thereby, improving survival [4].
The National Surgical Adjuvant Breast and Bowel Pro-
ject (NSABP) B-18 study comparing anthracycline-based
chemotherapy preoperatively with the same regimen
postoperatively has shown an enhanced rate of BCS
with NAC [5]. No survival difference was seen between
both groups. Other studies, including a recent meta-ana-
lysis, have also demonstrated comparable results [6-8].
Therefore, NAC can increase BCS rate, but the effect on
long-term survival remains unproven.
The optimal NAC schedule is unknown. Several stu-
dies have shown promising results of using taxanes fol-
lowing anthracyclines, particularly in terms of enhancing
a pathological complete response (pCR) rate, a surrogate
marker of long-term survival [6,9-11]. Nevertheless,
NAC is associated with significant morbidity and
reduced quality of life (QoL) [12,13].
Studies of weekly docetaxel in metastatic breast cancer
have demonstrated significantly reduced toxicity profiles,
while maintaining a level of efficacy comparable with
the 3-weekly regimen [14-16]. A phase II study of
weekly docetaxel alone as NAC has shown a high pCR
rate with less haematological toxicity [17]. A randomised
NAC study comparing weekly versus 3-weekly paclitaxel
followed by 4 cycles of 5-fluorouracil, doxorubicin, and
cyclophosphamide has confirmed a superiority of the
weekly schedule in enhancing a pCR rate [18]. Recently,
the results from the Intergroup Trial E1199 comparing
paclitaxel or docetaxel given preoperatively every 3
weeks or weekly following doxorubicin and cyclopho-
sphamide in operable breast cancer have demonstrated
no differences in disease-free survival (DFS) between
taxanes and schedules. However, DFS was significantly
improved with weekly paclitaxel and 3-weekly docetaxel,
compared with 3-weekly paclitaxel [19].
The primary aim of our study was to compare the
effects on QoL of weekly versus 3-weekly sequential
neoadjuvant docetaxel. Secondary aims were to deter-
mine the clinical and pathological responses, incidence
of Breast Conserving Surgery (BCS), Disease Free Survi-
val (DFS) and Overall Survival (OS).
Methods
Patient eligibility
Women (ages 18-70 years) presenting to the Lincoln
Breast Unit were invited to participate if they had uni-
lateral/bilateral large (≥3 cm) or LABCs (T3, T4, TxN2),
no distant metastases; WHO performance status of <2;
no history or evidence of abnormal cardiac function;
adequate haematological, renal, and hepatic function;
and were not pregnant.
E x c l u s i o nc r i t e r i aw e r eap r e vious malignancy (except
curatively treated carcinoma in situ of the cervix or
basal cell carcinoma of skin); previous cytotoxic, endo-
crine, or radiotherapy; active infection; contraindications
to corticosteroid administration; pre-existing neurotoxi-
city (> grade 2) (NCI-CTC); significant cognitive impair-
ment or dementia, and inability to complete QoL
questionnaires or provide informed consent.
The study protocol was approved by the Research
Ethical Committee. Patients provided signed informed
consent.
Study design
Diagnosis was established by examination (calliper mea-
surements), mammography, ultrasonography, and core
needle biopsy. All women underwent a chest radiograph,
bone scintigraphy and liver ultrasonography to exclude
metastases before entry.
Patient entry, participation, randomisation and treat-
ment are shown schematically in Figure 1. Randomisa-
tion was carried out using permuted blocks (Instat 2).
Treatment allocation was performed independently by a
third party, by opening sealed sequenced envelopes con-
taining treatment allocation. Tumour progression (local
or distant) on treatment resulted in withdrawal.
QoL was assessed before randomisation, every 3 weeks
during docetaxel, and 3 weeks after completion of
chemotherapy.
Tumour responses were assessed using calliper and
ultrasound measurements. Wide local excision or mas-
tectomy was performed with either sample or clearance
of the axillary lymph nodes. Pathological responses of
the tumour in the breast and metastatic lymph nodes
were assessed and graded. Patients having BCS received
radiotherapy to the breast. If sampling established
metastases, axillry and supraclavicular nodes were trea-
ted by radiotherapy. Patients who underwent mastect-
omy received radiotherapy to the chest wall if deemed
at risk of local recurrence. Tamoxifen was given to
patients whose tumours had receptors for oestrogen
(ER) and/or progesterone (PR).
Treatment regimen
Patients received intravenous injections of doxorubicin
(A) 60 mg/m
2 and cyclophosphamide (C) 600 mg/m
2
every 3 weeks for four cycles. The weekly group were
given twelve further cycles of docetaxel, 33 mg/m
2 as
one-hour intravenous infusions at weekly intervals with
a two-week break between cycle 6 and 7. Patients in the
3-weekly group received four further cycles of docetaxel
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2, as one-hour intravenous infu-
sions every 3 weeks. Patients received dexamethasone
and ondansetron, before and after therapy. Both groups
received identical total doses of docetaxel and steroids.
If the nadir neutrophil count on day 21 was <1.5 × 10
9/
L, with or without fever, or the platelet count <100 × 10
9/
L, the subsequent doses (A, C, or docetaxel) were reduced
by 25%; dose reductions were maintained during subse-
quent cycles. For a second episode of grade IV neutrope-
nia, the subsequent doses of chemotherapy were reduced
by 50%. Granulocyte colony-stimulating factor (G-CSF)
was given to patients with neutropenia-associated sepsis.
A delay of more than two weeks for haematological recov-
ery necessitated taking the patient off study.
Surgery
Patients underwent surgery 4 weeks after the last cycle
of chemotherapy; surgery was performed earlier if there
was tumour progression or prolonged toxicity. The type
of surgery carried out depended on the response to che-
motherapy, the amount of residual tumour, and patient
preference. Axillary surgery was performed in all cases,
either sampling (≥4 lymph nodes removed) or level I-III
dissection.
Figure 1 Schematic diagram of patient entry, subsequent randomisation and treatment regimens. Rx, treatment
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Radiotherapy was given according to cancer centre local
guidelines at the time. All patients who had undergone
breast conserving surgery had post-operative radiother-
apy. This consisted of the following (i) 50 Gy in 25 frac-
tions to the breast over 5 weeks. In addition, those aged
50 years or under received an electron boost of 16 Gy
in 8 fractions (ii) Following mastectomy and if more
than 3 cam residual tumour, vascular invasion, or T4
cancer on presentation, chest wall irradiation (45 Gy in
20 fractions over 4 weeks) was carried out
If lymph nodes were involved by metastatic disease
(assessed by sampling, level I/II dissection), the remain-
ing axillary and supraclavicular lymph nodes were irra-
diated (45 Gy in 20 fractions over 4 weeks). If clearance
was performed (level III) and lymph nodes were
involved only the supraclavicular area was irradiated (45
Gy in 20 fractions over 4 weeks).
Anti-hormonal
All patients with ER +ve and/or PR +ve breast cancers
received tamoxifen 20 mg daily for 5 years.
Quality of life
Before randomisation, and three weeks after completion of
docetaxel, patients completed the Functional Assessment
of Cancer Therapy-Breast (FACT-B) questionnaire (ver-
sion 3) and the Rotterdam Symptom Checklist (RSCL)
[20,21]. FACT-B assesses physical, social, emotional, func-
tional wellbeing, and additional concerns specific to
women with breast cancer. Patients indicated how true a
statement had been for them over the past 7 days using a
5-point scale. High scores equate with a good QoL and
low scores with a poor QoL. The RSCL yields separate
measures for psychological and physical symptoms.
During docetaxel treatment (every 3 weeks), patients
completed the Hospital Anxiety and Depression Scale
(HADS), the Mood Rating Scale (MRS), the Global Dis-
tress Scale (GDS), and the Treatment Side-Effects Ques-
t i o n n a i r e( T S E Q )w h i c hm e a s u r e st h ep r e s e n c ea n d
severity of possible side-effects on a 5-point scale (not
present; present but not distressing; slightly distressing,
very distressing, and extremely distressing)[12,22-24].
Clinical response
Tumour response was assessed during each cycle and on
completion of chemotherapy by calliper and ultrasound
measurements. Responses were graded according to the
International Union Against Cancer criteria [25]; an
absence of clinical evidence of tumour was classified as
a complete clinical response (cCR); >50% reduction in
the product of the two maximum perpendicular dia-
meters of the tumour was classified as a partial clinical
response (cPR); ≥25% increasing in size was classified as
clinically progressive disease (cPD); clinical response
that does not meet the definition of cCR, cPR, or cPD
was classified as stable disease (cSD). Assessment of
response after completion of NAC was made with refer-
ence to the size of tumour recorded prior to commence-
ment of chemotherapy.
Pathological response
Breast and axillary specimens were received fresh by the
pathology department, thinly sliced and immersed in
10% neutral-buffer formalin for optimal fixation. All
specimens were examined histologically using haematox-
ylin and eosin staining by a breast pathologist. Tumour
response was evaluated using the Miller and Payne grad-
ing system [26]; grade 1, some alteration to individual
malignant cells but no reduction in overall numbers as
compared with the pre-treatment core biopsy; grade 2, a
mild loss of invasive tumour cells but overall cellularity
still high; grade 3, a considerable reduction in tumour
cells up to an estimated 90% loss; grade 4, a marked dis-
appearance of invasive tumour cells such that only small
clusters of widely dispersed cells could be detected;
grade 5, no invasive tumour cells identifiable in the sec-
tions from the site of the previous tumour (e.g., only in-
situ disease or fibrosis remained). Metastatic nodes were
assessed for pathological response (grade 1-5). Grade 5
response of the primary tumour represented a pCR.
Outcome measures
The primary outcome was the Trial Outcome Index
(TOI) of the FACT-B questionnaire; TOI is the sum of
the scores from the physical, functional wellbeing, and
breast cancer subscales (23 items in total) [27,28].
Higher TOI scores are associated with better QoL [29].
The secondary QoL outcomes were RSCL, HADS, MRS,
GDS, and TSEQ.
Other outcomes were the clinical and pathological
r e s p o n s e s ,i n c i d e n c eo fB C S ,D F S ,a n dO S .D F Si st h e
time from randomisation to local, regional, or distant
treatment failure; occurrence of contralateral breast can-
cer; or death. OS is the time from randomisation to
death from any cause.
Statistical methods
Means and standard deviations of the TOI of FACT-B,
obtained in our previous NAC study, suggested that a
sample size of 40 in each group would have 80% power
to detect a 6% difference in means using a two sample
t-test with alpha at p = 0.05 (two-tailed) [12]. Allowance
for the subject drop out was arbitrarily set at 15-20%.
Therefore, it was necessary to recruit 95-100 patients
into the trial.
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(FACT-B, RSCL, HADS, and MRS) at the primary end-
point (3 weeks after completion of chemotherapy) were
analysed using Analysis of Covariance (ANCOVA) (with
pre-randomisation values as covariate).
Because of non-normality of the distributions,
between-treatment differences in GDS and each item of
TSEQ were analysed for the primary endpoint (3 weeks
after completion of chemotherapy) and the secondary
endpoints (at 3, 6, and 9 weeks during docetaxel admin-
istration) using the Exact Probability-linear by linear test
[30].
Comparisons of response outcomes between the treat-
ment groups were analysed using the Chi-square test.
Logistic regression analysis was performed to evaluate
predictors of a pCR. Survival curves were estimated
using the Kaplan-Meier method, and treatment compar-
isons were carried out using the log-rank test [31]. The
Cox regression model was used to compute hazard
ratios (HRs) and 95% confidence intervals (CIs), to
examine the effect of prognostic variables, and to test
for interactions between treatment and covariates. P
values < 0.05 were considered statistically significant.
Data were analysed using SPSS for Windows version
15.0. All those completing treatment were included in
the analysis.
Results
Randomisation and enrollment
From July 2000 to November 2002, 96 patients were
enrolled (Figure 1). One withdrew prior to commencing
treatment; three withdrew before completion of AC
(metastatic or progressive disease). Ninety-two patients
completed four initial cycles of AC; three declined
further chemotherapy, due to toxicity. Eighty-nine
patients underwent treatment stratification, 45 were ran-
domised to receive twelve further cycles of weekly doce-
taxel and 44 to receive four further cycles of 3-weekly
docetaxel. Three patients declined further chemotherapy
due to toxicity and two withdrew because of progressive
disease. Two patients had metastatic disease after the
third and fifth cycles of weekly docetaxel. Eighty-two
patients (41 in each group) completed all cycles of che-
motherapy and underwent surgery.
Patient features and tumour characteristics
The groups were evenly matched for age, menopausal
status, tumour size, tumour grade, clinical staging, and
hormonal status (Table 1). The mean age was 49 years
(range 27-70). Mean tumour calliper measurement was
4.2 cm (range 2.0-11.4). Over 80% of the cancers were
T2 tumours. More than half were grade 3 and more
than two-thirds expressed ER (>10% of cells).
QoL
Primary outcome
Adjusted mean scores for TOI and other secondary QoL
outcomes are shown in Table 2. There were no signifi-
cant differences in TOI scores between the weekly and
3-weekly groups at the primary endpoint (3 weeks after
Table 1 Patient features and tumour characteristics
Characteristic Weekly
docetaxel
(n = 41)
3-weekly
docetaxel
(n = 41)
P-value
No. (%) No. (%)
Age (years) 0.38
Mean 50.1 48.3
Range 27-68 32-70
Age at entry (years) 0.08
≤50 17 42 25 61
>50 24 58 16 39
Menopausal status 0.66
Premenopausal 22 54 24 58
Postmenopausal 19 46 17 42
Tumour size (cm) by caliper 0.41
Mean 4.1 4.3
Range 2.0-6.2 2.5-11.4
Tumour size (cm) by ultrasound 0.40
Mean 2.3 2.4
Range 0.9-4.6 1.0-4.7
Tumour stage 0.77
T1 1 2 0 0
T2 32 79 35 86
T3 7 17 5 12
T4 1 2 1 2
Tumour type 0.48
Invasive ductal 35 85 38 93
Invasive lobular 6 15 3 7
Tumour grade 0.21
15 1 2 1 2
21 6 3 9 1 5 3 7
32 0 4 9 2 5 6 1
Clinical staging 0.39
IIA 22 53 15 37
IIB 15 37 18 44
IIIA 2 5 3 7
IIIB 2 5 5 12
Oestrogen receptor status 0.24
Positive 31 76 25 61
Negative 10 24 15 37
Unknown 0 0 1 2
Progesterone receptor status 0.09
Positive 21 51 13 32
Negative 13 32 23 56
Unknown 7 17 5 12
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in each subscale of FACT-B between groups were seen.
Secondary outcomes
At the primary endpoint, there were no significant dif-
ferences in RSCL, physical and psychological scores
between groups. There were also no significant differ-
ences between groups in HADS anxiety and depression
scores. Weekly group had significantly lower MRS total
scores, compared with the 3-weekly group (p = 0.01);
only MRS-energy subscale showed a significant differ-
ence (p = 0.04).
Of the 19 side-effects, only one was significant: neuro-
pathy was present in 38.2% and rated significantly more
distressing in the 3-weekly group (c
2 =7 . 2 0 5 ,p =
0.008). Overall, 39.5% rated their last 3 weeks treatment
as ‘not distressing’. However, distress (GDS) was signifi-
cantly greater in the 3-weekly group (c
2 =4 . 9 9 ,p =
0.034).
Weekly docetaxel had significantly lower GDS scores
at 3 weeks (c
2 = 17.42.
p < 0.001), 6 weeks (c
2 = 10.063, p = 0.001), and 9
weeks (c
2 = 7.910, p = 0.005) during docetaxel
administration. At least at one of these time points,
patients in the weekly group had significantly less diar-
rhoea, constipation, nail problems, neuropathy, tired-
ness, pain, distress, depressed mood, and unhappiness.
Clinical responses
The overall response rate (ORR: cCR + cPR) in 92
patients after four initial cycles of AC was 63% (Table
3). For the 82 patients who completed all cycles of doce-
taxel, ORRs were 93% in the weekly and 90% in the 3-
weekly groups; 63% of patients in the weekly and 54% in
the 3-weekly groups had achieved a cCR (p =0 . 3 7 ) .
Sixty-five evaluable patients who did not achieve a cCR
after AC, 58 (89%) were characterised as clinical respon-
ders after treatment with docetaxel.
Ultrasonographic ORR of the tumour, in 92 patients
after completion of AC, was 59%. For 82 patients rando-
mised to weekly and 3-weekly docetaxel, ORRs were
81% and 71%, respectively (p = 0.30). The ultrasono-
graphic cCR was equal (29%) in both groups.
Pathological responses
In 82 patients, there was no significant difference in the
pCR rate between groups (20% in the weekly and 27%
in the 3-weekly groups, p = 0.43) (Table 4).
Approximately two-thirds of patients in both groups
had no evidence of nodal involvement. Of 29 patients
having involved nodes, 16 (55%) had no evidence of
nodal response following chemotherapy (grade 1); only
4 (14%) had complete response with scarring and
fibrosis.
Using multivariate logistic regression analysis, none of
the variables (age, clinical nodal status, and clinical tumour
size) were statistically significant predictors of a pCR.
Operative procedure
Almost half the patients (49% in the weekly and 42% in
the 3-weekly groups) underwent BCS. Eight (20%) in the
weekly and 5 (12%) in the 3-weekly groups required
further surgery to achieve satisfactory clearance (p =
0.36). In patients with a cCR, 69% had BCS, compared
with 27% without a cCR (p < 0.001). Thirty-four (83%)
patients in the weekly and 39 (95%) in the 3-weekly
groups underwent axillary sampling (p = 0.16). The rest
of the patients, in both treatment groups, underwent
axillary clearance.
Compliance and toxicity
Six patients withdrew due to chemotherapy-related toxi-
city (three had AC only); mean number of chemother-
apy cycles received by these patients was four.
There was no significant difference in the total
intended drug dose of AC and docetaxel between
groups. Five (6%) patients required a dose reduction of
Table 2 Primary and secondary outcomes at three weeks
after completion of chemotherapy
QoL scales Weekly
docetaxel
3-weekly
docetaxel
F P-
value
Adjusted
mean (SE)
Adjusted
mean (SE)
FACT
TOI 63.78 (1.66) 64.20 (1.68) 0.030 0.86
Physical 21.20 (0.73) 21.63 (0.74) 0.172 0.68
Social 22.79 (0.62) 23.23 (0.64) 0.241 0.63
Emotional 19.21 (0.51) 19.32 (0.51) 0.024 0.88
Functional 19.80 (0.71) 18.48 (0.72) 1.691 0.20
Additional 22.85 (0.59) 24.02 (0.60) 1.921 0.17
RSCL
Physical 38.40 (1.14) 37.47 (1.14) 0.335 0.57
Psychological 12.79 (0.50) 11.76 (0.50) 2.057 0.16
HADS
Anxiety 4.53 (0.44) 4.26 (0.44) 0.196 0.66
Depression 4.12 (0.39) 3.14 (0.39) 3.237 0.08
MRS
Relaxation 88.59 (6.64) 104.49 (6.64) 2.708 0.10
Happiness 93.67 (6.29) 106.72 (6.29) 2.045 0.16
Energy 40.65 (6.12) 59.01 (6.12) 4.443 0.04
Clear-
headedness
103.41 (5.90) 106.51 (5.90) 0.138 0.71
Easygoingness 94.63 (6.17) 94.37 (6.17) 0.001 0.98
Confidence 98.25 (6.07) 105.91 (6.07) 0.744 0.39
Total 548.27 (22.68) 637.64 (23.28) 7.101 0.01
Abbreviations: QoL, quality of life; SE, standard error; FACT, functional
assessment of cancer therapy; TOI, trial outcome index; RSCL, Rotterdam
symptom checklist; HADS, hospital anxiety and depression scale; MRS, mood
rating scale.
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G-CSF support.
Of the 82 patients, only 5 (6%) experienced grade 3-4
neutropenia; 4 (5%) had febrile neutropenia only during
AC administration. A higher percentage of patients in
the 3-weekly groups experienced asthenia, neuropathy,
peripheral oedema, and nail problems; the reverse was
true for epiphora (Table 5). No death-related toxicity
occurred during treatment.
Survival
The median time on study with follow-up was 71.5
months. Of 82 patients, 21 (26%) experienced recur-
rences, of which 14 died (Table 6). The 5-year DFS
were 76% in the weekly and 73% in the 3-weekly groups
(p = 0.8). No difference in OS was seen between groups
(81% in the weekly and 85% in the 3-weekly groups, p =
0.66) (Figure 2).
Age at entry was a highly significant predictor of survi-
val. Women >50 years had significantly better DFS (88%
vs. 62%, p = 0.006) and OS (95% vs. 71%, p =0 . 0 0 4 ) ,
compared with those who were ≤ 50 years (Figure 3).
These remained significant differences when adjusted for
clinical tumour size, clinical and pathological nodal sta-
tus, and tumour grade. The pCR and pathological nodal
status were not predictors for survival in this study.
Discussion
There has been an increasing interest in the use of NAC
to downstage breast cancer and possibly increasing long-
term survival. New drug combinations (antracyclines
and taxanes) have been shown to be effective. Studies
have suggested that the sequential use of docetaxel fol-
lowing AC is optimal. To improve efficacy and reduce
morbidity, weekly taxanes have been used in patients
with both advanced cancer and in the adjuvant setting. .
The weekly regimen has demonstrated better tolerabil-
ity, whilst maintaining efficacy comparable with the
3-weekly regimen[32,33].
Table 3 Clinical and ultrasound responses after
completion of chemotherapy
Response 4AC
(n = 92)
Weekly
docetaxel
(n = 41)
3-weekly
docetaxel
(n = 41)
P-value
No. % No. % No. %
Clinical response
cCR 17 18 26 63 22 54 0.70
cPR 41 45 12 29 15 37
cSD 31 34 1 3 3 7
cPD 1 1 2 5 1 2
NA 2 2 0 0 0 0.0
ORR 58 63 38 93 37 90
US response
cCR 16 19 12 29 12 29 0.71
cPR 37 40 21 51 17 41
cSD 27 29 7 17 8 20
cPD 2 2 0 0.0 0 0
NA 9 10 1 3 4 10
ORR 53 59 33 81 29 71
Abbreviations: AC, doxorubicin+cyclophosphamide; cCR, clinical complete
response; cPR, clinical partial response; cSD, clinical stable disease; cPD, clinical
progressive disease; NA, not assessable; ORR, overall response rate (cCR+cPR);
US, ultrasound
Table 4 Pathological responses and nodal status after
completion of chemotherapy
Pathological response Grade Weekly
docetaxel
(n = 41)
3-weekly
docetaxel
(n = 41)
P-value
No. % No. %
Primary tumour 1 10 24 7 17 0.90
2 5 12 4 10
31 1 2 7 1 1 2 7
4 7 17 8 19
5 8 20 11 27
Lymph node
Negative 25 61 28 68 0.86
Positive 1 8 19 8 20
22 500
32 525
40 000
52 525
NA 2 5 1 2
Abbreviation: NA, not assessable
Table 5 Treatment-related toxicity
Toxicity Weekly docetaxel
(n = 41)
3-weekly docetaxel
(n = 41)
P-value
No. % No. %
Nausea 3 7 5 12 0.71
Vomiting 3 7 2 5 1.00
Stomatitis 3 7 4 10 1.00
Asthenia 4 10 7 17 0.33
Neuropathy 0 0 16 38.2 0.008
Peripheral oedema 5 12 12 29 0.57
Epiphora (tearing) 13 32 8 20 0.21
Nail problems 9 22 15 37 0.15
Table 6 Recurrences and death
Overall Weekly docetaxel
(n = 41)
3-weekly docetaxel
(n = 41)
P-value
No. % No. %
Recurrence 10 24 11 27 0.80
Locoregional 4 10 3 7 1.00
Contralateral 0 0 2 5 0.49
Distant 10 24 8 20 0.59
Death 8 20 6 15 0.49
Walker et al. BMC Cancer 2011, 11:179
http://www.biomedcentral.com/1471-2407/11/179
Page 7 of 11To the best of our knowledge, this is the first report
on QoL, psychosocial scores, and, concurrently, clinical
and pathological responses of weekly versus 3-weekly
docetaxel following pre-treatment with AC in the
neoadjuvant setting. Three-weekly docetaxel is the stan-
dard regimen used in many centres treating patients
with metastatic breast cancer. A weekly docetaxel
regimen has not been shown to be superior, in a similar
sized study to ours, in patients with metastatic breast
cancer [34]. In a recently published radnomised con-
trolled trial in women with metastic breast cancer, a
weekly regimen (n = 77) compared with a 3 weekly regi-
men (n = 79) did not demonstrate a superior therapeu-
tic outcome or quality of life [34]. However, a large
Figure 2 Kaplan-Meier survival curves of (A) disease-free survival and (B) overall survival between treatment groups. HR, hazard ratio;
CI, confidence interval; (–), weekly docetaxel; (—), 3-weekly docetaxel
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versus 3 weekly regimens of paclitaxel in advanced
breast cancer has clearly demonstrated better overall
survival in the weekly regimen group (1471 patients,
fixed effect model pooled HR 0.78, 95%CI 0.67-0.89 p =
0.001), as well as sigfnificantly reduced toxicity [35].
Our findings indicated that docetaxel, given weekly or
3-weekly, demonstrated similar generic measures of
QoL (FACT-TOI, FACT-B, RSCL, HADS). The weekly
group had lower distressing scores and reported less
diarrhoea, constipation, nail problems, neuropathy, pain,
tiredness, distress, depressed mood, and unhappiness.
Figure 3 Kaplan-Meier survival curves of (A) disease-free survival and (B) overall survival between age groups at study entry.H R ,
hazard ratio; CI, confidence interval; (–), women >50 years; (—), women ≤50 years
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Page 9 of 11However, not all women preferred the weekly regimen,
as it often interfered with a busy life schedule which
probably explains the significantly lower energy and
total MRS scores. Moreover, the weekly regimen
requires more resources, thus, this need to be taken into
consideration when planning the treatment regimens.
Our study has confirmed the results from other phase
III studies of sequential docetaxel following anthracy-
cline-based regimens. Two studies have evaluated
weekly docetaxel only as NAC in stage II and III breast
cancer [17,36]. In 56 patients, the ORR was 68%; 9
patients (16%) achieved a pCR. Another study rando-
mised 913 patients with operable breast cancer to four
cycles of preoperative doxorubicin combined with doce-
t a x e le v e r y2w e e k so rf o u rc y c l e so fA Cf o l l o w e db y
four cycles of docetaxel every 3 weeks [11]. The sequen-
tial regimen had a higher ORR (85% vs. 75%; p <0 . 0 0 1 )
and pCR rate (22% vs. 11%; p <0 . 0 0 1 ) .T h ew e e k l y
group in our study has shown an ORR of 93% and pCR
rate of 20%, comparable with these results.
The pathological response within involved nodes was
similar between the treatment groups. Only 14% of
metastatic nodes showed a pCR. This result suggests
that NAC is more effective in killing the primary
tumour than the metastatic cells in the axillary nodes.
Our study also documented a similar incidence of BCS
in both groups.
The total intended drug dose and regimen duration in
both groups were comparable. The weekly regimen was
not associated with grade 3-4 neutropenia. All patients
had a WHO performance status of 0, which may have
contributed to the lower incidence of toxicity. A higher
incidence of epiphora, as documented in our study, has
been reported previously [37-39].
The Aberdeen study has shown that the addition of
docetaxel to anthracycline-based NAC significantly
increased the pCR rate and a 3-year DFS and OS [40].
However, the NSABP B-27 did not show a significant
difference despite doubling the pCR rate [6]. In our
study, the overall 5-year DFS and OS, irrespective of
treatment schedule, were 74% and 83%, and the pCR
rate was 23%. These results confirm the benefit of doce-
taxel with anthracycline-based regimens in NAC.
Several studies have shown that the pCR and pathologi-
cal nodal status are predictors of long-term survival. Our
study, however, did not confirm this, possibly due to the
small cohort of patients. In this study, age at entry was a
significant independent predictor for survival.
Conclusions
Our small study confirms the benefits of using sequen-
tial weekly docetaxel in NAC for women with large or
LABCs. Although the QoL was not significantly differ-
ent, the lower distressing side-effect and the favorable
toxicity profile may indicate the use of the weekly regi-
men for certain groups of patients, particularly the older
patients or those with poor performance status. These
beneficial effects require an increased number of clinic
visits and more staff-time, but are not at the expense of
clinical and pathological responses, BCS and survival
outcomes.
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